BRIEF-Arena Pharmaceuticals Reports Q1 Loss Per Share $0.80

* EXPECT TO INITIATE PHASE 3 STUDIES FOR RALINEPAG IN PULMONARY ARTERIAL HYPERTENSION IN SECOND HALF OF 2018